ORALLY INHALED AND NASAL DRUG PRODUCT
This article was originally published in The Gold Sheet
Executive Summary
...manufacturers are exploring how quality-by-design concepts apply in the context of the complexities of the drug/device interface. The challenges surrounding the control of leachables and extractables and how the supplier relationships fit into the QbD effort are particular focal points of attention. New industry guidances on L&Es and supplier GMPs from the Product Quality Research Institute and the International Pharmaceutical Aerosol Consortium on Regulation and Science, respectively, are helping move the dialogue forward and tighten the communication linkages. [Summary reports from three breakout sessions at a recent IPAC-RS conference – on supplier quality control, parametric tolerance interval testing and application of ISO standards – are provided.]
You may also be interested in...
The Quality Lowdown: DSCSA, Recalls, Extractables & Leachables And Nitrosamines
The US FDA refines guidance on verification systems for suspect drug products and voluntary recalls, while industry groups issue guidance on extractables and leachables in parenteral drugs and the role of excipients in nitrosamine formation.
Revised US Approach For Parenteral Drug Leachables Could Prevent Regulatory Missteps
Broad agreement across US FDA on modified PQRI recommendations could reduce approval delays over risk of chemicals leaching into parenteral drugs.
McKinsey Survey Highlights Progress, Challenges in Adoption of QbD
Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.